ARGS Argos Therapeutics, Inc.

0.46
+0.054  (13%)
Previous Close 0.41
Open 0.42
Price To book 0.00
Market Cap 18.98M
Shares 41,351,000
Volume 3,451,162
Short Ratio 2.50
Av. Daily Volume 1,166,830

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial recommended be discontinued for futility - February 22, 2016. Noted April 18, 2017 that it intends to continue the trial to 290 events (analysis of overall survival) - late 2017 or early 2018.
AGS-003 ADAPT Trial
Metastatic renal cell carcinoma (mRCC)
Phase 2 initiated 1Q 2016. Ongoing as of November 2016.
AGS-003
Non-Small Cell Lung Cancer
Phase 2 second stage commenced dosing July 2016. Ongoing as of March 2017.
AGS-004
HIV
Phase 2 trial initial data due 2H 2017.
AGS-003
Early stage renal cell carcinoma (RCC) - cancer

Latest News

  1. Argos CEO talks company plans to move forward
  2. ARGS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Argos Therapeutics, Inc. and a Lead Plaintiff Deadline of May 15, 2017
  3. Argos Provides Update on its ADAPT Trial Following Meeting with FDA
  4. SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Argos Therapeutics, Inc. To Contact The Firm Before Imminent Lead Plaintiff Deadline
  5. Argos Therapeutics faces threat of delisting
  6. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Complaint Filed in U.S. District Court to Recover Losses Suffered by Investors in Argos Therapeutics, Inc. - Lead Plaintiff Deadline of May 15, 2017 - ARGS
  7. Robbins Arroyo LLP Reminds Investors of Lead Plaintiff Deadline in Argos Therapeutics, Inc. (ARGS) Class Action
  8. The Klein Law Firm Announces the Commencement of a Class Action Filed on Behalf of Argos Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of May 15, 2017
  9. DEADLINE ALERT: Brower Piven Alerts Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Those with Losses in Excess of $100,000 from Investment in Argos Therapeutics, Inc. to Contact the Firm
  10. Argos Reports Interim Results of the ADAPT Trial and Provides Perspective on Decision to Continue the Trial
  11. Chief medical officer departs troubled Argos
  12. The Klein Law Firm Announces a Class Action Has Been Filed on Behalf of Argos Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of May 15, 2017
  13. ETFs with exposure to Argos Therapeutics, Inc. : April 7, 2017
  14. The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics
  15. EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders it Has Filed in U.S. District Court to Recover Losses Suffered by Investors in Argos Therapeutics, Inc. - Sets Lead Plaintiff Deadline of May 15, 2017 - ARGS
  16. 3 of the Best & Worst Performing Drug Stocks of Q1
  17. SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Argos Therapeutics, Inc. (ARGS) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
  18. ARGS INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Argos Therapeutics, Inc. and a Lead Plaintiff Deadline of May 15, 2017
  19. INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Has Filed in U.S. District Court to Recover Losses Suffered by Investors in Argos Therapeutics, Inc.
  20. INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Argos Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit